albuterol and Infant, Premature, Diseases

albuterol has been researched along with Infant, Premature, Diseases in 14 studies

Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Infant, Premature, Diseases: Diseases that occur in PREMATURE INFANTS.

Research

Studies (14)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Association of Smoke Exposure During Pregnancy and Neonatal Response to Albuterol

Mothers who smoked cigarettes during pregnancy and the rate of albuterol response of their infants (NCT02447250)
Timeframe: Smoking and second hand smoke exposure history will be obtained at enrollment. Albuterol response will be obtained within one week.

Birth Weight of Albuterol Responders vs Non Responders

birth weight in grams of each subject was recorded at time of enrollment (NCT02447250)
Timeframe: within one week of entering study

Change in Respiratory Resistance

The primary outcome is the percentage of subjects who show a positive response to each dose of albuterol. A positive response is defined as a greater than or equal to 10% decrease in respiratory resistance (Rrs). The change in RRs was measured at baseline and again after each dose of albuterol. All measurements were taken within a 7 day time frame for each subject such that each subject would have up to 3 results measured during a 7 day period, if he/she were able to complete three sets of PFTs according to study protocol. The change in Rrs was calculated by subtracting the baseline Rrs from the post-albuterol Rrs. (NCT02447250)
Timeframe: Within one week of performing pulmonary function tests

Etiology of Preterm Delivery

Reason for each subject's preterm delivery was classified as either preterm labor or delivery for maternal indications (eg pre-eclampsia). (NCT02447250)
Timeframe: within one week of entering study

Family History of Asthma and Likelihood to Respond to Albuterol

Family history was obtained from verbal history by subject's mother at time of enrollment in study. A positive family history was noted if a first degree relative of the subject (infant) had a diagnosis of asthma. (NCT02447250)
Timeframe: History collected at enrollment, albuterol response assessed within one week

Gestational Age at Birth

Average gestational age (GA) in weeks at birth for subjects who responded to albuterol versus subjects without a positive response (NCT02447250)
Timeframe: within one week of entering study

Maternal BMI at Time of Pregnancy and Likelihood of Positive Response to Albuterol

Maternal BMI will be obtained from her medial record, and she will be asked about weight gain during pregnancy at time of enrollment. Results will be compared for infants born to women with a normal BMI vs. those with obese BMI (>30). (NCT02447250)
Timeframe: Maternal information collected at enrollment; albuterol response assessed within one week

Number of Participants With Positive Response at Different Albuterol Doses

Compare number of subjects who have a positive response (greater than or equal to 10% decrease in respiratory resistance) to each dose of albuterol (NCT02447250)
Timeframe: Data collected 15 minutes after dose in each session. Study includes 3 sessions within a 7 day period.

Reviews

6 reviews available for albuterol and Infant, Premature, Diseases

Trials

4 trials available for albuterol and Infant, Premature, Diseases

Other Studies

4 other studies available for albuterol and Infant, Premature, Diseases